Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, it will present new clinical and pre-clinical data supporting its vision to extend the reach of cancer immunotherapies to new patient populations, in an oral presentation and four poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between 3-5 November 2023, San Diego, CA.
Oral presentation details:
Abstract Title: Harnessing natural IL-18 activity through IL-18BP blockade reshapes the tumor microenvironment for potent anti-tumor immune response
Abstract number: 550
Presenter: Eran Ophir
Session: Cytokines in Cancer
Date: Friday, November 3, 2023
Time: 3:30 PM – 5:10 PM PDT
Poster presentation details:
Abstract Title: Immune modulation and baseline biomarker correlation with clinical benefit following treatment with COM701 + nivolumab +/- BMS-986207 in patients with platinum resistant ovarian cancer
Abstract Number: 29
First Author: Gady Cojocaru
Date: Friday, November 3, 2023
Abstract Title: Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancer
Abstract Number: 669
First Author: Stephanie Gaillard
Date: Friday, November 3, 2023
Abstract Title: Harnessing natural IL-18 activity through IL-18BP blockade reshapes the tumor microenvironment for potent anti-tumor immune response
Abstract number: 550
First Author: Assaf Menachem
Date: Saturday, November 4, 2023
Abstract Title: The combination of COM701 + nivolumab demonstrates preliminary antitumor activity in patients with metastatic breast cancer
Abstract Number: 640
First Author: Ecaterina Dumbrava
Date: Saturday, November 4, 2023
Compugen’s abstracts will be available on the publications section of Compugen’s website, www.cgen.com
